|
|
News Breaks | | | | February 10, 2013 | | 18:55 EDT |  | NVO, SNY, LLY | Novo Nordisk receives FDA 'Complete Response Letter" for Tresiba and Ryzodeg
Novo Nordisk announced that on 8 February it received a Complete Response Letter from the US Food and Drug Administration, FDA, regarding the New Drug Applications for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart). A complete Response Letter is issued by the FDA, when the agency determines that an application cannot be approved in its current form. Reference Link | |
|
News For NVO;SNY;LLY From The Last 14 Days Check below for free stories on NVO;SNY;LLY the last two weeks. |
|
|
| There are no results for NVO;SNY;LLY |
|
|
|
|
|
|
